glp-1 and liver Why are agonists being used to treat patients with nonalcoholic fatty disease? glp 1 drugs and fatty

Patients in Longview observing tirzepatide treatment have reported substantial weight reduction, often between 15 to 20 percent of their initial body weight in controlled studies spanning 72 weeks

Individual variation in immune response means some users will develop antibodies against any peptide-based medication, regardless of how closely it matches human sequences

Effect of alpha-lipoic acid on asymmetric dimethylarginine and disability in multiple sclerosis patients: A randomized clinical trial

However, discontinuing GLP-1 injections may result in weight regain, emphasizing the importance of long-term management, lifestyle modifications, and healthy eating habits

This effect was observed across DSIP concentrations ranging from 10 to 10 M, showing a 10-20% elevation

doi: 10.1016/j.fct.2011.06.071 80